Abstract
Methods are now available for the sensitive detection and quantitation of carcinogen-DNA adducts which do not depend upon radiolabeled carcinogens. These methods are essential for the measurement of adducts in humans with exposure to environmental and occupational carcinogens. Measurement of carcinogen-DNA adducts in the target tissue, termed biologically effective dose, is believed to be a more relevant marker of exposure than measurement of the chemical itself either in the environment or in body fluids (1). Such assays take into account individual differences in absorption and metabolism of carcinogens as well as repair of adducts. Since target tissue (e.g., lung, liver) is not available on a routine basis from healthy individuals, white blood cells have been utilized in a number of biomonitoring studies as a surrogate source of DNA.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
F.P. Perera and I.B. Weinstein, Molecular epidemiology and carcinogen-DNA adduct detection: New approaches to studies of human cancer causation. J.Chron. Dis. 35, 581–600 (1982).
M.C. Poirier, The use of carcinogen-DNA adduct antisera for quantitation and localization of genomic damage in animal models and the human population. Environ Mutag. 6, 879–887 (1984).
R.M. Santella, Application of new techniques for the detection of carcinogen adducts to human population monitoring. Mutat. Res. 205, 271–282 (1988).
E. Hebert, G. Saint-Ruf, and M. Leng, Immunological titration of 3-N-acetyl-hydroxyamino-4,6-dimethyldipyrido(1,2-a:3’,2’-d)imidazolerat liver DNA adducts. Carcinogenesis 6, 937–939 (1985).
E. Sage, R.P. Fuchs, and M. Leng, Reactivity of the antibodies to DNA modified by the carcinogen N-acetoxy-N-acetyl-2-aminofluorene. Biochemistry 18, 1328–1334 (1979).
M. Leng, E. Sage, R.P.P. Fuchs, and M.P. Daune, Antibodies to DNA modified by the carcinogen N-acetoxy-N-2-acetylaminofluorene. FEES Lett. 92, p. 207 (1978).
S.S. Ball, V. Quaranta, F. Shadravan, and R.L. Walford, An ELISA for detection of DNA-bound carcinogen using a monoclonal antibody to N-acetoxy-2-acetylaminofluorene-modified DNA. J. Immunol. Methods 98, 195–200 (1987).
M.C. Poirier, S.H. Yuspa, I.B. Weinstein, and S. Blobstein, Detection of carcinogen-DNA adducts by radioimmunoassay. Nature (London) 270, 186–188 (1977).
M. Guigues and M. Leng, Reactivity of Antibodies to Guanosine Modified by the Carcinogen N-acetoxy-N-2-acetylaminofluorene. Nucleic Acids Res. 6, 733–744 (1979).
C.J. Van der Laken, A.M. Hagenaars, G. Hermsen, E. Kriek, A.J. Kuipers, J. Nagel, E. Scherer, and M. Welling, Measurement of 06-ethyldeoxyguanosine and N-(deoxyguanosine-8-yl)-N-acetyl-2aminofluorene in DNA by high-sensitive enzyme immunoassays. Carcinogenesis 3, 569–572 (1982).
R.A. Baan, M.J. Lansbergen, P.A.F. Bruin, M.I. Willems, and P.H.M. Lohman, The organ-specific induction of DNA adducts in 2-acetylaminofluorenetreated rats, studied by means of a sensitive immunochemical method. Mutat. Res 150, 23–32 (1985).
A. Haugen, J.D. Groopman, I.C. Hau, G.R. Goodrich, G.W. Wogan, and C.C. Harris, Monoclonal antibody to aflatoxin B1-modified DNA detected by enzyme immunoassay. Proc. Natl. Acad. Sci. USA 78, 4124–4127 (1981).
P.J. Hertzog, J.R.L. Smith, and R.C. Garner, Production of monoclonal antibodies to guanine imidazole ring opened aflatoxin B1 DNA, the persistent DNA adduct in vivo. Carcinogenesis 3, 825–828 (1982).
D.W. Roberts, R.W. Benson, J.D. Groopman, T.J. Flammang, W.A. Nagle, A.J. Moss, and F.F. Kadlubar, Immunochemical quantitation of DNA adducts derived from the human bladder carcinogen, 4-aminobiphenyl. Cancer Res. 48, 6336–6342 (1988).
M.C. Poirier, J. Nakayama, F.P. Perera, I.B. Weinstein, and S.H. Yuspa, Identification of carcinogen-DNA adducts by immunoassays. In: “Application of Biological Markers to Carcinogen Testing” (H.A. Milman and S. Sell, Eds.), pp. 427–440. Plenum, New York, 1983.
P. Rio and M. Leng, Antibodies to N-(guanosine-8-y1)-2-aminofluorene. Biochimie 62, 487–490 (1980).
L.L. Hsieh, A.M. Jeffrey, and R.M. Santella, Monoclonal antibodies to 1-aminopyrene-DNA. Carcinogenesis 6, 1289–1293 (1985).
M.C. Poirier, R. Santella, I.B. Weinstein, D. Grunberger, and S.H. Yuspa, Quantitation of benzo[a]pyrene-deoxyguanosine adducts by radioimmunoassay. Cancer Res. 40, 412–416 (1980).
R.M. Santella, C.D. Lin, W.L. Cleveland, and I.B. Weinstein, Monoclonal antibodies to DNA modified by a benzo[a]pyrene diol epoxide. Carcinogenesis 5, 373–377 (1984).
H. Slor, N. Mizusawa, T. Nechart, R. Kakefuda, R.S. Day, and M. Bustin, Immunochemical visualization of binding of the chemical carcinogen benzo[a]pyrene diol epoxide to the genome. Cancer Res. 41, 3111–3117 (1981).
F.J. van Schooten, E. Kriek, M.S.T. Steenwinkel, H.P.J.M. Noteborn, M.J.X. Hillebrand, and F.E. vanLeeuwen, The binding efficiency of polyclonal and monoclonal antibodies to DNA modified with benzo[a]pyrene diol epoxide is dependent on the level of modification. Implications for quantitation of benzo[a]pyrene-DNA adducts in vivo. Carcinogenesis 8, 1263–1269 (1987).
R. Muller and M.F. Rajewsky, Antibodies specific for DNA components structurally modified by chemical carcinogens. J. Cancer Res. Clin. Oncol. 102, 99–113 (1981).
B. Malfoy, B. Hartmann, J.P. Macquet, and M. Leng, Immunochemical studies of DNA modified by cis-dichlorodiaamine platinum (II). Cancer Res. 41, 4127–4131 (1981).
M.C. Poirier, S. Lippard, L.A. Zwelling, M. Ushay, D. Kerrigan, R.M. Santella, D. Grunberger, and S.H. Yuspa, Antibodies elicited against cis-diamminedichloroplatinum(II)-modified DNA are specific for cis-diamminedichloroplatinum(II)-DNA adducts formed in vivo and in vitro. Proc. Natl. Acad. Sci. USA 79, 6443–6447 (1982).
A. Fichtinger-Schepman, R. Baan, A. Luiten-Schuite, M. VanDijk, and P.H.M. Lohman, Immunochemical quantitation of adducts induced in DNA by cis-diamminedichloroplatinum(II) and analysis of adduct related DNA-unwinding. Chem-Biol. Interact. 55, 275–288 (1985).
R. Mustonen, K. Hemminki, A. Alhonen, P. Hietanen, and M. Kiilunen, Determination of cis-diamminedichlorodiplatinum (II) in blood compartments of cancer patients. In: “Detection Methods for DNA-Damaging Agents in Humans an: Applications in Cancer Epidemiology and Prevention” (K. Hemminki and H. Bartsch, Eds.). IARC, Lyon, 1988.
W.I. Sundquist, S.J. Lippard and B.D. Stollar, Monoclonal antibodies to DNA modified with cis-or trans-diamminedichloroplatinum (II). Proc. Natl. Acad. Sci. USA 84, 8225–8229 (1987).
P.G. Foiles, F.L. Chung, and S.S. Hecht, Development of a monoclonal antibody based immunoassay for cyclic DNA adducts resulting from exposure to crotonaldehyde. Cancer Res. 47, 360–363 (1986).
T.L. Young and R.M. Santella, Development of techniques to monitor for exposure to vinyl chloride: monoclonal antibodies to ethenoadenosine and ethenocytine. Carcinogenesis 9, 589–592 (1988).
G. Eberle, A. Barbin, R.J. Laib, F. Ciroussel, J. Thomale, H. Bartsch, and M.F. Rajewsky, 1,N6-etheno-2’-deoxyadenosine and 3,N4-etheno2’deoxycytidine detected by monoclonal antibodies in lung and liver DNA of rats exposed to vinyl chloride. Carcinogenesis 10, 209–212 (1989).
R. Muller and M.F. Rajewsky, Immunological quantification by high-affinity antibodies of 06-ethyldeoxyguanosine in DNA exposed to N-ethyl-N-nitrosourea. Cancer Res. 40, 887–896 (1980).
M.F. Rajewsky, R. Muller, J. Adamkiewicz, and W. Drosdziok, Immunological detection and quantification of DNA components structurally modified by alkylating carcinogens. In: “Carcinogenesis: Fundamental Mechanisms and Environmental Effects” (B. Pullman, P.O.P. Tso and H. Gelboin, Eds.), pp. 207–218. Reidel Publ. Co., Dordrecht and Boston, 1980.
M.J. Tilby, J.M. Styleg, and C.J. Dean, Immunological Detection of DNA Damage Caused by Melphalan Using Monoclonal Antibodies. Cancer Res. 47, 1542–1546 (1987).
R.M. Santella, N. Dharmaraja, F.P. Gasparro, and R.L. Edelson, Monoclonal antibodies to DNA modified by 8-methoxypsoralen and ultraviolet A light. Nucleic Acids Res, 13, 2533–2544 (1985).
Z. Zarebska, M. Jarbabek-Chorzelska, T. Chorzelski, and S. Zablonska, Immune serum against anti DNA-8-methoxypsoralen photoadduct. Z. Naturforsch 39, 136–140 (1984).
C.P. Wild, G. Smart, R. Saffhill and J.M. Boyle, Radioimmunoassay of 06methyldeoxyguanosine in DNA of cells alkylated in vitro and in vivo. Carcinogenesis 4, 1605–1609 (1983).
T.W. Munns, M.K. Liszewski, H.F. Sims, et al, Characterization of antibodies specific for N6-methyladenosine and for 7-methylguanosine. Biochemistry 16, 2163–2168 (1977).
R.D. Meridith and B.F. Erlanger, Isolation and characterization of rabbit anti-m7G-5’-P antibodies of high apparent affinity. Nucleic Acids Res. 6, 2179–2191 (1979).
P. Degan, R. Montesano, and C.P. Wild, Antibodies against 7-methyldeoxyguanosine: Its detection in rat peripheral blood lymphocyte DNA and potential applications to molecular epidemiology. Cancer Res. 48, 5065–5070 (1988).
A.M. Stein, H.G. Gratzner, J.H. Stein, and M.M. McCabe, High avidity monoclonal antibody to imidazole ring-opened ethylguanine. Carcinogenesis 10, 927–973 (1989).
P.T. Strickland and J.M. Boyle Immunoassay of carcinogen-modified DNA. In: “Progress in Nucleic Acid Research & Molecular Biology” (W.E. Cohn Ed.), pp. 1–58. Academic Press, New York, 1984.
T. Morita, S. Ikeda, Y. Minoura, M. Kojima and M. Tada, Polyclonal antibodies to DNA modified with 4-nitroquinoline 1-oxide application for the detection of 4-nitroquinoline 1-oxide-DNA adducts in vivo. J. Cancer Res,79, 195–203 (1988).
G. Miolo, M. Stefanidis, R.M. Santella, F. Acqua, and F. Gasparro, 6,4,4’-Trimethylangelecin photoadduct formation in DNA: production and characterization of a specific monoclonal antibody. Photochem. Photobiol. 3, 101–112 (1989).
P.T. Strickland and J.M. Boyle, Characterisation of two monoclonal antibodies specific for dimerised and non-dimerised adjacent thymidines in single stranded DNA. Photochem. Photobiol. 34, 595–601 (1981).
A.A. Wani, R.E. Gibson-D’Ambrosio, and M.D. D’Ambrosio, Antibodies to UV Irradiated DNA: the monitoring of DNA damage by ELISA and indirect immunofluorescence. Photochem. Photobiol, 40, 465–471 (1984).
R.D. Ley, Immunological detection of two types of cyclobutane pyrimidine dimers in DNA. Cancer Res, 43, 41–45 (1983).
S.A. Leadon and P.C. Hanawalt, Monoclonal antibody to DNA containing thymine glycol. Mutat. Res. 112, 191–200 (1983).
D. Randerath, M.V. Reddy, and R.A.C. Gupta, [32P]-labeling test for DNA damage. Proc. Natl. Acad. Sci. USA 78, 6126–6129 (1981).
M.V. Reddy, R.C. Gupta, E. Randerath, and K. Randerath, 32P-Postlabeling test for covalent DNA binding of chemicals in vivo: application to a variety of aromatic carcinogens and methylating agents. Carcinogenesis 5, 231–243 (1984).
V.L. Wilson, A.K. Basu, J.M. Essigmann, R.A. Smith, and C.C. Harris, 06-Alkyldeoxyguanosine detection by 32P-postlabeling and nucleotide chromatographic analysis. Cancer Res. 48, 2156–2161 (1988).
R.C. Gupta and K. Earley, 32P-adduct assay: comparative recoveries of structurally diverse DNA adducts in the various enhancement procedures. Carcinogenesis 9, 1687–1693 (1988).
M.V. Reddy and K. Randerath, Nuclease P1-mediated enhancement of sensitivity of [32P]-postlabeling test for structurally diverse DNA adducts. Carcinogenesis 7, 1543–1551 (1986).
C.C. Harris, K. Vahakangas, J.M. Newman, G.E. Trivers, A. Shamsuddin, N. Sinopoli, D.L. Mann, and W.E. Wright, Detection of benzo[a]pyrene diol epoxide-DNA adducts in peripheral blood lymphocytes and antibodies to the adducts in serum from coke oven workers. Proc. Natl. Acad. Sci. USA 82, 6672–6676 (1985).
A. Weston, M.I. Rowe, D.K. Manchester, P.B. Farmer, D.L. Mann, and C.C. Harris, Fluorescence and mass spectral evidence for the formation of benzo(a)pyrene anti-diol-epoxide-DNA and -hemoglobin adducts in humans. Carcinogenesis 10, 251–257 (1989).
A.M. Jeffrey, I.B. Weinstein, K.W. Jennette, K. Grzeskowiak, K. Nakanishi, R.G. Harvey, H. Autrup, and C. Harris, Structures of benzo[a]pyrene-nucleic acid adducts formed in human and bovine bronchial explants. Nature (London) 269, 348–350 (1977).
R.M. Santella, F.P. Gasparo, and L.L. Hsieh, Quantitation of carcinogen-DNA adducts with monoclonal antibodies. Prog. in Exp. Tumor Res. 31, 63–75 (1987).
R.M. Santella, A. Weston, F.P. Perera, G.T. Trivers, C.C. Harris, T.L. Young, D. Nguyen, B.M. Lee and M.C. Poirier, Interlaboratory comparison of antisera and immunoassays for benzo(a)pyrene-diolepoxide-I-modified DNA. Carcinogenesis 9, 1265–1269 (1988).
X.Y. Yang, V. DeLeo, and R.M. Santella, Immunological detection and visualization of 8-methoxypsoralen-DNA photoadducts. Cancer Res. 47, 2451–2455 (1987).
F.P. Perera, K. Hemminki, T.L. Young, R.M. Santella, D. Brenner, and G. Kelly, Detection of polycyclic aromatic hydrocarbon-DNA adducts in white blood cells of foundry workers. Cancer Res. 48, 2288–2291 (1988).
D.H. Phillips, K. Hemminki, A. Alhonen, A. Hewer, and P.L. Grover, Monitoring occupational exposure to carcinogens: detection by 32P-Postlabeling of aromatic DNA adducts in white blood cells from iron foundry workers. Mutat. Res. 204, 531–541 (1988).
K. Hemminki, E. Grzybowska, M. Chorazy, K. Twardowska-Saucha, J.W. Sroczynski, K.L. Putnam, K. Randerath, D.A. Phillips, H. Hewer, R.M. Santella, T.L. Young, and F.P. Perera, DNA adducts in humans environmentally exposed to aromatic compounds in an industrial area of Poland. Carcinogenesis 11, 1229–1231 (1990).
R.B. Everson, E. Randerath, R.M. Santella, R.C. Cefalo, T.A. Avitts, and K. Randerath, Detection of smoking-related covalent DNA adducts in human placenta. Science 231, 54–57 (1986).
R.B. Everson, E. Randerath, R.M. Santella, T.A. Avitts, I.B. Weinstein, and K. Randerath, Quantitative associations between DNA damage in human placenta and maternal smoking and birth weight. J. Natl. Cancer Inst. 80, 567–576 (1988).
F. Perera, J. Mayer, A. Jaretzki, S. Hearne, D. Brenner, T.L. Young, K. Fischman, M.X. Grimes, S. Grantham, Tang, W.Y. Tsai and R.M. Santella, Comparison of DNA adducts and sister chromatid exchange in lung cancer cases and controls. Cancer Res. 49, 4446–4451 (1989).
B. Paigen, E. Ward, A. Reilly, L. Houten, H.L. Gurtoo, K. Minowada, J. Steenland, M.B. Havens, and P. Satori, Seasonal variation of aryl hydrocarbon hydroxylase activity in human lymphocytes. Cancer Res. 41, 2757–2761 (1981).
L. Shugart, Quantifying adductive modification of hemoglobin from mice exposed to benzo[a]pyrene. Anal. Biochem. 152, 365–369 (1986).
H. Wallin, A.M. Jeffrey, and R.M. Santella, Investigation of benzo[a]pyrene-globin adducts. Cancer Lett. 35, 139–146 (1987).
B.M. Lee and R.M. Santella, Quantitation of protein adducts as a marker of genotoxic exposure: immunologic detection of benzo(a)pyrene-globin adducts in mice. Carcinogenesis 9, 1773–1777 (1988).
A. Weston, G. Trivers, J.K. Vahakangas, M. Newman, and M. Rowe, Detection of carcinogen-DNA adducts in human cells and antibodies to these adducts in human sera. Prog. Exp. Tumor Res. 31, 76–85 (1987).
IARC monographs on the evaluation of the carcinogenic risks of chemicals to humans: polynuclear aromatic compounds, IARC, Lyon (1984).
D.R. Bickers, The carcinogenicity and mutagenicity of therapeutic coal tar--A perspective. J. Invest. Dermatol 77, 173–174 (1981).
A.R. Pittelkow, H.O. Perry, S.A. Muller, W.Z. Maughan, and P.C. O’Brien, Skin cancer in patients with psoriasis treated with coal tar. Arch. Dermatol. 117, 465–468 (1981).
R.S. Stern, S. Zierler, and J.A. Parrish, Skin carcinoma in patients with psoriasis treated with topical tar and artificial ultraviolet radiation. Lancet 2, 732–733 (1980).
R.S. Stern, J. Scotto, and T.R. Fears, Psoriasis and susceptibility to non-melanoma skin cancer. J. Am. Acad. Dermatol. 12, 67–73 (1985).
J.S. Storer, I. DeLeon, L.E. Millikan, J.L. Laseter, and C. Griffing, Human absorption of crude coal tar products. Arch. Dermatol. 120, 874–877 (1984).
F.J. Jongeneelen, R.B.M. Anzion, C.M. Leijdekkers, R.P. Bos, and P.T. Henderson, 1-Hydroxypyrene in human urine after exposure to coal tar and a coal tar derived product. Int. Arch. Occup, Environ. Health 57, 47–55 (1985).
E. Clonfero, M. Zordan, D. Cottica, P. Venier, L. Pozzoli E.L. Cardin, F. Sarto, and A.G. Levis, Mutagenic activity and polycyclic aromatic hydrocarbon levels in urine of humans exposed to therapeutical coal tar. Carcinogenesis 7, 819–823 (1986).
E. Clonfero, M. Zordan, P. Venier, M. Paleologo, A.G. Levis, L. Cottica, D. Pozzoli, F.J. Jongeneelen, R.P. Bos and R.B.M. Ansion, Biological monitoring of human exposure to coal tar locus in Chinese hamster ovary cells. Int. Arch. Occup. Environ. Health 61, 363–368 (1989).
L.A. Wheeler, M.D. Saperstein, and N.J. Lowe, Mutagenicity of urine from psoriatic patients undergoing treatment with coal tar and ultraviolet light. J. Invest. Dermatol. 77, 181–185 (1981).
F. Sato, M. Zordan, R. Tomanin, D. Mazzotti, A. Canova, E.L. Cardin, G. Bezze, and A.G. Levis, Chromosomal alterations in peripheral blood lymphocytes, urinary mutagenicity and excretion of polycyclic aromatic hydrocarbons in six psoriatic patients undergoing coal tar therapy. Carcinogenesis 10, 329–334 (1989).
M.C. Poirier, J.R. Stanley, J.B. Beckwith, I.B. Weinstein, and S.H. Yuspa, Indirect immunofluorescent localization of benzo[a]pyrene adducted to nucleic acids in cultured mouse keratinocyte nuclei. Carcinogenesis 3, 345–348 (1982).
S.A. Lesko, D.E. Callahan, D.S. Kaplan, W. Li, W.R. Midden, P.T. Strickland, and G. Zheng, Quantitative immunofluorescence assay for cyclobutyldithimidine dimers in individual mammalian cells. Carcinogenesis 10, 641–646 (1989).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer Science+Business Media New York
About this chapter
Cite this chapter
Santella, R.M. et al. (1991). Biological Monitoring of Exposure to Polycyclic Aromatic Hydrocarbons. In: Nygaard, O.F., Upton, A.C. (eds) Anticarcinogenesis and Radiation Protection 2. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3850-9_25
Download citation
DOI: https://doi.org/10.1007/978-1-4615-3850-9_25
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6718-5
Online ISBN: 978-1-4615-3850-9
eBook Packages: Springer Book Archive